New study to measure drug levels in breast milk of moms on TREMFYA
NCT ID NCT07654751
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 4 times
Summary
This study will measure how much of the drug TREMFYA (guselkumab) passes into breast milk of 10 nursing women who are already taking it for conditions like psoriasis, psoriatic arthritis, ulcerative colitis, or Crohn's disease. Researchers will collect milk samples to estimate the daily dose a baby might receive. The goal is to provide better information for mothers who need this medication while breastfeeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Guselkumab (TREMFYA)
- What this could lead to
- If successful, this study could provide important safety information for breastfeeding women who need TREMFYA for conditions like psoriasis or Crohn's disease.
- What could go wrong
- This is a very small study (10 participants) that only measures drug levels in milk, not infant health outcomes. It cannot determine if the drug is safe for babies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.